Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial.

Viral N ShahAmer Al-KaradshehCathy BarnesJose MandrySamer NakhleKarin Wernicke-PantenDaniel KramerWolfgang SchmiderSuzanne PierreLenore TeichertBaerbel RotthaeuserBhaswati Mukherjee Timothy S Bailey

Published in: Journal of diabetes science and technology (2024)

Alternating doses of SAR-Asp and NN-Asp compared with continuous use of NN-Asp showed similar safety, immunogenicity, and clinical efficacy in adults with T1D. This study supports interchangeability between SAR-Asp and NN-Asp in T1D management.

Keyphrases

type diabetes
glycemic control
clinical trial
randomized controlled trial
metabolic syndrome
phase ii